Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT00660621
Title A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma
Recruitment Unknown status
Gender both
Phase Phase II
Variant Requirements No
Sponsors Kentuckiana Cancer Institute, Eisai Inc.
Indications

brain glioma

Therapies

Bevacizumab + Temozolomide

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.